购物车
- 全部删除
- 您的购物车当前为空
Atibuclimab 是一种靶向 CD14 的嵌合单克隆抗体,由小鼠可变区和人类 IgG4 Fc 区构成。Atibuclimab 可用于治疗肌萎缩侧索硬化症。Atibuclimab 可减少 LPS 诱导的病症,并对 LPS 诱导的促炎细胞因子释放有抑制作用,可延迟抗炎细胞因子可溶性 TNF 受体 I 型的释放,
为众多的药物研发团队赋能,
让新药发现更简单!
Atibuclimab 是一种靶向 CD14 的嵌合单克隆抗体,由小鼠可变区和人类 IgG4 Fc 区构成。Atibuclimab 可用于治疗肌萎缩侧索硬化症。Atibuclimab 可减少 LPS 诱导的病症,并对 LPS 诱导的促炎细胞因子释放有抑制作用,可延迟抗炎细胞因子可溶性 TNF 受体 I 型的释放,
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,650 | 现货 | |
5 mg | ¥ 4,630 | 现货 | |
10 mg | ¥ 6,490 | 现货 | |
25 mg | ¥ 9,630 | 现货 | |
50 mg | ¥ 12,900 | 现货 | |
100 mg | ¥ 17,500 | 现货 |
产品描述 | Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I. |
别名 | 阿替布利单抗 |
CAS No. | 2417175-94-9 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.